ESSA Pharma

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It focuses on developing novel and proprietary therapies for the treatment of prostate cancer in patients, whose disease is progressing despite treatment with standard of care therapies, including second-generation anti-androgen drugs such as abiraterone, enzalutamide, apalutamide and darolutamide. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It engages in the business of developing small molecule drugs for the treatment of prostate cancer. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 6, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be participating in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m. ET. David.

ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Jan. 25, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of updated dose escalation data from its Phase 1/2 study evaluating masofaniten (formerly EPI-7386) in combination with enzalutamide at the 2024 ASCO Genitourinary Cancers Symposium, taking place January 25 - 27, 2024, in San Francisco, CA. Masofaniten is a first-in-class N-terminal domain androgen receptor ("AR") inhibitor that suppresses androgen activity through a novel mechanism of action and is being developed for the treatment of prostate cancer.

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium

Phase 1 dose escalation complete for masofaniten (EPI-7386)/enzalutamide combination study in patients with mCRPC; compelling safety and efficacy data reported at Prostate Cancer Foundation 2023 Scientific Retreat and ESMO 2023 Head-to-head Phase 2 dose expansion underway evaluating masofaniten (EPI-7386)/enzalutamide combination versus enzalutamide monotherapy in patients with mCRPC SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Dec. 12, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company, focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2023.  "We are pleased with the progress made in 2023 with masofaniten (EPI-7386), our first-in-class N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer, which culminated recently in the presentation of Phase 1 dose escalation data at two medical meetings where we showed that the combination of masofaniten with enzalutamide was well-tolerated and demonstrated deep and durable reductions in prostate-specific antigen ("PSA") in patients with metastatic castration-resistant prostate cancer ("mCRPC")," said David Parkinson, MD, President and CEO of ESSA.

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Nov. 21, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Piper Sandler 35th Annual Healthcare Conference on Thursday, November 30, 2023, at 12:00 p.m. ET in New York.

ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada , Nov. 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Wednesday, November 15, 2023, at 8:30 a.m.

ESSA Pharma to Present at the Jefferies London Healthcare Conference

A phase 2 study is being advanced using EPI-7386 in combination with enzalutamide to treat patients with metastatic castration-resistant prostate cancer; Positive updated PSA data presented at medical conference. EPI-7386 is being advanced as a monotherapy to treat patients with metastatic castration-resistant prostate cancer who have progressed on prior standard of care therapies. Additional studies are being done in collaboration with Janssen and Bayer to test the use of EPI-7386 in combination with other drugs for the treatment of mCRPC patients.

ESSA Pharma: Unique N-Terminal Domain Approach Might Hinder mCRPC Resistance

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Nov. 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has entered into an Open Market Sale AgreementSM (the "ATM Sales Agreement") with Jefferies LLC, effective as of November 3, 2023. Under the ATM Sales Agreement, ESSA may sell its common shares in the capital of the Company from time to time for up to US$50.0 million in aggregate sales proceeds.

ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement

Recommended Phase 2 dose regimen identified as masofaniten 600mg BID combined with enzalutamide 160mg QD Phase 2 head-to-head portion of the study to commence enrollment immediately Updated Phase 1 results selected for a poster presentation at ESMO 2023 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada , Sept.

ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada , Aug. 31, 2023 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that each of its President and Chief Executive Officer, David R Parkinson and its Executive Vice President and Chief Operating Officer, Peter Virsik (collectively, the "Participants"), have established Automatic Securities Disposition Plans ("ASDPs") in accordance with applicable United States and Canadian securities legislation, including U.S. Securities and Exchange Commission ("SEC") Rule 10b5-1 and the recommended practices set forth in the Canadian Securities Administrators' Staff Notice 55-317 ("Staff Notice 55-317") and the Company's internal policies.

ESSA Pharma Insiders Establish Automatic Securities Disposition Plans

Completion of the Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide) expected in the third calendar quarter of 2023 followed by initiation of the randomized Phase 2 part of the study Entered into clinical trial support agreement with Janssen to supply Erleada® (apalutamide) and Zytiga® (abiraterone acetate) for an ESSA-sponsored Phase 1 study of EPI-7386 combination therapies; enrollment expected to begin 2H2023 Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing SAN FRANCISCO, California and VANCOUVER, Canada , Aug. 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2023. All references to "$" in this release refer to United States dollars, unless otherwise indicated.

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , June 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Lauren Merendino, M.B.A., to its Board of Directors.

ESSA Pharma Appoints Lauren Merendino to its Board of Directors

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , June 1, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 8:00 a.m. Eastern Time in New York.

ESSA Pharma to Present at 2023 Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , May 11, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 10:00 a.m. Eastern Time in New York.

ESSA Pharma to Present at JMP Securities Life Sciences Conference

Entered into clinical trial support agreement with Janssen to supply Erleada® (apalutamide) and Zytiga® (abiraterone acetate) for an ESSA-sponsored Phase 1 study of EPI-7386 combination therapies; enrollment expected to begin 2H2023 Continue to enroll patients into the fourth cohort of the Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide); Phase 1 completion expected in 3Q2023 followed by initiation of the randomized Phase 2 part of the study Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , May 9, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2023. All references to "$" in this release refer to United States dollars, unless otherwise indicated.

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023

SOUTH SAN FRANCISCO, Calif., and VANCOUVER, Canada , April 12, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company has entered into a clinical trial support agreement (the "Agreement") with Janssen Research & Development, LLC ("Janssen") to enable evaluation of ESSA's first-in-class N-terminal domain androgen receptor inhibitor, EPI-7386, in combination with apalutamide as well as the combination of EPI-7386 with abiraterone acetate plus prednisone in patients with prostate cancer.

ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , March 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the virtual Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023, at 11:20 a.m. Eastern Time.

ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 13, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that further analyses of initial clinical data from two Phase 1 studies of EPI-7386 in patients with metastatic castration-resistant prostate cancer ("mCRPC") will be presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium ("ASCO GU"), taking place February 16-19, 2023, in San Francisco, California and online. EPI-7386 is a first-in-class N-terminal domain androgen receptor ("AR") inhibitor that suppresses androgen activity through a novel mechanism of action.

ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)

Completion of Phase 1 EPI-7386 combination study with enzalutamide expected in 1H2023 followed by initiation of the randomized Phase 2 study Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing SOUTH SAN FRANCISCO, CALIFORNIA and VANCOUVER, Canada , Feb. 7, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2022. All references to "$" in this release refer to United States dollars, unless otherwise indicated.

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022

EPIX is targeting prostate cancer with its lead and only asset EPI-7386. While there's some rationale to the molecule's science, there's not a lot of convincing data yet.

ESSA Pharma: One Asset, One Program Company With Little Data

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 2, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will participate in a fireside chat at the Guggenheim Healthcare Talks 5th Annual Oncology Conference in New York City on Thursday, February 9, 2023, at 9:00 a.m. Eastern Time.

ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference

SOUTH SAN FRANCISCO, CALIFORNIA and VANCOUVER, CANADA , Dec. 13, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2022. All references to "$" in this release refer to United States dollars, unless otherwise indicated.

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022

The stock has pulled back from the 2x pop after the recent data of EPI-7386+Xtandi in post-chemotherapy metastatic castration-resistant prostate cancer, mCRPC. The efficacy of the EPI-7386+Xtandi combination in mCRPC beats that of currently approved drugs by a significant margin.

ESSA Pharma: EPI-7386+Xtandi Combination Has Shown Highest Efficacy In Metastatic, Castration-Resistant Prostate Cancer

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Nov. 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be participating in two upcoming investor conferences. David. R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will participate in and host one-on-one meetings.

ESSA Pharma to Participate in Two Upcoming Investor Conferences

Johnson & Johnson

Shares of Essa Pharma Inc. EPIX, +1.38% fell 28.6% in premarket trading on Monday after the company said Johnson & Johnson JNJ, +1.49% suspended enrollment in a Phase 1 clinical trial for Essa's experimental prostate cancer therapy, citing patient recruitment challenges. Essa had announced a clinical collaboration with J&J back in 2021.

J&J suspends enrollment in clinical trial assessing Essa Pharma's prostate cancer treatment

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Oct. 31, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Janssen Research and Development ("Janssen") is suspending enrollment into the Phase 1 clinical study of EPI-7386 with apalutamide or EPI-7386 with abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer ("mCRPC") patients as a result of operational recruitment challenges.   Before suspending enrollment, Janssen treated three mCRPC patients (pre-chemotherapy) with the combination of EPI-7386 and apalutamide or abiraterone acetate plus prednisone for up to four months of therapy.

News for ESSA Pharma Stock (EPIX)